---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-105037"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:09:20.104688+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Korro Bio closes $70M private placement to fund Phase 1/2 trial of KRRO-110

## Summary
- Sold 1,249,283 shares at $56.00 per share for gross proceeds of ~$70M.
- Led by Deep Track Capital; includes Atlas Venture, Blue Owl, NEA, Rock Springs, Tri Locum.
- Proceeds plus existing $166.4M cash to fund Phase 1/2 trial of KRRO-110 in AATD through 2026.
- Piper Sandler, RBC Capital, BMO Capital Markets acted as placement agents.

## SEC filing metadata
- accession: 0001193125-24-105037
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312524105037/0001193125-24-105037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312524105037/d814636d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-105037
- JSON: https://secwatch.observer/filing/0001193125-24-105037.json
- Plain text: https://secwatch.observer/filing/0001193125-24-105037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.